ShangBay Capital is a venture capital firm that specializes in early-stage investments in healthcare startups. The firm focuses on bridging the gap between China and the United States by investing in innovative life science and medical technology companies that have the potential to create significant value in both markets.

ShangBay Capital is a venture capital company that brings both U.S. and global investors access to best-in-class investments in the U.S. medical devices, biotechnology, and digital health sectors through early-stage venture equity participation. Since our establishment in 2015, we have invested in over 50+ portfolio companies and have been ranked as the Most Active Medical Device VC across both the U.S. and Europe in 2020 and 2021.

Lucira Health

Berkeley Lights

ShangBay Capital

Our Portfolio Company, neuro42, attracts investment from surgical robot industry pioneer, Dr. Fred Moll, and appoints him as a strategic investor. Congratulations to the neuro42 team! 👏 

https://lnkd.in/g4XPXnSN

Congratulations to Abcuro, Inc for successfully closing a $155M oversubscribed Series B round co-led by Redmile Group and Bain Capital Life Sciences! Abcuro is a biotech firm specializing in the development of immunotherapies for autoimmune diseases and cancer.

#biotech #seriesb #venturecapital 
https://lnkd.in/g6i_2sdF

Delighted to share that in the first half of 2023, we at ShangBay Capital achieved the distinction of being the most active Medical Device investor as reported by the HSBC Innovation Banking Team. Kudos to the entire ShangBay team for their outstanding efforts!

#venturecapital #healthcare #medtech

Luminopia has announced the close of a $16 million oversubscribed Series A financing round. This round was led by U.S. Venture Partners, with participation from their new investor Broadfin Advisors, and their existing investors ShangBay Capital and Vertical Group. 

#funding #venturecapital #amblyopia #seriesa 
https://lnkd.in/eNBvxJVg

Presidio Medical, a clinical-stage medical technology company developing a transformational Ultra Low-Frequency neuromodulation platform, has closed a $72 million Series C funding round. This round was led by Deerfield Management, existing investors, and joined by ShangBay Capital.

#medtech #venturecapital #funding 
https://lnkd.in/ghATzR5M

Excited to announce our participation in Solenic Medical's Series A Financing, lead by our friends at J&J Innovation! Solenic is developing a device that uses alternating magnetic fields to treat prosthetic joint infections.


#venturecapital #medtech #earlystage

Great panel discussion at 2023 Wilson Sonsini MedTech and Digital Health Conference….

Noah Medical, one of ShangBay's portfolio companies, has announced that its Galaxy System™ received FDA clearance for its robotic navigated bronchoscopy. Noah Medical's platform is the only robotic navigated bronchoscopy system on the market to integrate real-time tomosynthesis and utilize a disposable bronchoscope, ushering in a new era in lung nodule biopsy. Congratulations to the Noah Medical team!

https://lnkd.in/dug9F9xW

COM:SHANGBAYCAPITAL

ShangBay Capital

Analysis Not Available